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Objectives
• Describe emerging trends in infectious disease
• Recognize epidemiologic risk factors for emerging and resurgent 
infectious disease
• Develop a differential diagnosis that includes appropriate 
infectious disease
Unanticipated Epidemics since 1980
• Staphylococcus aureus toxic 
shock
• S aureus USA 300
• AIDS
• West Nile virus
• Lyme disease
• Avian influenza
• Severe acute respiratory 
syndrome (SARS)
• Middle Eastern respiratory 
syndrome (MERS)
• Legionnaires' disease
• Measles
• Ebola
• Cryptosporidiosis
• H1N1 influenza ("swine flu")
• Iatrogenic fungal meningitis
• Clostridium difficile NAP1 strain
• Norovirus ("cruise-ship 
dysentery")
• Anthrax bioterrorism
Recent and Current Epidemics
• World Wide
• Zika Virus
• Yellow Fever
• Ebola
• Dengue
• Chikungunya
• Enterovirus
• Influenza
• Middle Eastern Respiratory 
Syndrome
• In the US and California
• Zika Virus
• West Nile Virus
• Meningitis
• Multi Drug Resistant Organisms
• Clostridium difficile Infections
• Community Acquired Pneumonia
• Influenza
• Vaccine Preventable Illness
• Measles, others
Viral Hemorrhagic Fevers
• From one of 4 families
• Flaviviridae (Dengue)
• Bunyaviridae (Hanta)
• Arenaviridae (Lassa)
• Filoviridae (Ebola)
• All but Dengue may be spread by aerosol
• All cause increased vascular permeability and in severe cases 
systemic inflammatory response, shock, organ failure and death.
• Mortality ranges from 10% (Dengue) to 90% (Ebola)
Zika Virus
• Originally discovered in the Zika forest of Entebbe, Uganda in primates in 1947.  
Sporadic small outbreaks in 2007, 2013 and 2014 in equatorial region. Brazil 
January 2016, developing pandemic.
• An arbovirus (arthropod borne) in the genus Flaviviridae.
• Dengue, yellow fever, WNV, St. Louis encephalitis, Japanese encephalitis all in the same 
genus
• ssRNA about 11k bases, 40 microns in size and is enveloped
• Enters host cell via membrane fusion, replicating in the cytoplasm and is shed 
via budding
• Humans are one of many hosts.  Zika can reproduce in arthropods and 
vertebrates
• Vector is the Aedesmosquito, but is also sexually transmitted and crosses the 
placenta (in utero transmission)
Current Zika active transmission as of 8/2/16
US Zika cases as of 8/3/16
US range of Aedes mosquitos
Source: CDC
Zika vector: Aedes mosquitos
• Aedes aegypti
• Tropical, sub-tropical and somewhat in temperate climates
• Prefer to feed on humans, and will feed during the day
• Aggressive: will follow you inside your house 
• Have developed localized resistance to several insecticides
• Aedes albopictus
• Tropical and sub-tropical, but can live at a broader range of temperate climates than 
aegypti
• Will feed on animals or humans
• Aggressive, generally hang out around where humans live.
• Both like small sheltered containers to lay eggs
• Eggs are hearty and can withstand desiccation for one year, but perish at <10°C
Zika Signs and Symptoms
• Incubation period of 3-12 days, 80% of infections go unnoticed.
• Most are asymptomatic, but if symptomatic will be so for 2-7 days
• Viremia is high in first week of illness and virus is shed for several days after 
resolution of symptoms.
• Rash, fever, and arthralgia are the main sypmtoms
• Fine, diffuse maculopapular rash including palms and soles
• Arthralgia predominates in small joints of hands and feet
• Myalgias and HA may also occur
• Differential diagnosis is broad but should include other arboviruses 
common in area of travel
• Dengue, chickungunya, etc
Zika Rash
emedicine.medscape.com
/article/2500035-clinical
Diagnostic Studies for Zika
• Lab
• Reverse transcriptase polymerase chain reaction (RT-PCR) will become 
positive during the initial week.
• After the 1st week anti-Zika IgM by ELISA will be positive but has cross 
reactivity with other flavivirus’ 
• Individual flavivirus antibody can be tested by plaque reduction 
neutralization tests (PRNT)
• CDC recommends urine or serum RT-PCR, if neg, then IgM with PRNT
• Urine samples remain positive for RT-PCR for at least two weeks longer than 
serum.
Complications and Treatment of Zika
• Really only a risk in pregnancy
• Microcephaly incidence increased 20 fold in Brazil since outbreak
• Also causes ophthalmologic abnormalities
• Guillian-Barre Syndrome (GBS) has been reported following Zika
• Current treatment consists of supportive therapy
• Avoid NSAIDS due to possible increased risk of bleeding (like Dengue)
• IvIg for severe GBS
• In those who are pregnant careful monitoring and evaluation of the fetus 
is indicated
• US for microcephaly or intracranial calcifications
• Amniotic fluid testing for Zika
Prevention of Zika
• Control of vectors
• DEET, mosquito nets, permethrin, long sleeves and pants
• Reduce standing water, insecticide spraying, 
• Genetically modified mosquitos: offspring are incapable of survival1
• Chinese have infected mosquitos with wolbachia bacteria which causes 
infertility of female if from mating, or the offspring if female is infected from 
other means2
• Avoid intercourse or use condoms for 28 days after illness or travel
• Wait 8 weeks to attempt to conceive, men 6 months.
• Vaccine in development
• One in Phase 1 trial, others developing
1. medscape.com/viewarticle/867009. 2. medscape.com/viewarticle/866928
Chikungunya Virus (CV)
• Originally discovered in 1952 in Tanzania, Africa
• Name means “to be bent over” in Swahili. Known as “buka-buka” 
in the Congo, which means “broken-broken”, probably due to the 
debilitating arthralgias caused by the virus
• Arbovirus in the Togaviridae family, alpha virus genus (different 
family from Dengue and Zika)
• Others in the same genus and family: WEE, EEE, Ross river virus
• ssRNA virus, about 11k bases, with envelope.  Cell entry is under 
study
Chikungunya Virus (CV)
• Characterized by outbreaks and long periods of quiescence
• Outbreak in the Americas since June 2014
• 2014 – 2811 cases in continental US and 4710 in territories
• 12 locally transmitted cases in FL, almost all locally transmitted in territories
• 2015 – 896 cases in continental US, and 237 in territories
• 1 locally transmitted in TX, almost all locally transmitted in territories
• 2016 – 59 cases in continental US, and 99 in territories
• No locally transmitted cases in continental US, almost all locally transmitted in 
territories
Current or previous CV as of 4/22/2016
Image source: CDC
Chikungunya in the US as of 8/9/16
Image source: CDC
Range of Aedes mosquitos US
Chikungunya Virus (CV)
• Major vector is Aedes aegypti, but CV mutated in 2006 to a form 
that could be transmitted by Aedes albopictus.
• Humans are the major reservoir during epidemics, but birds, 
primates, and rodents may be also in quiescent periods.
• Travel to endemic areas is the major risk factor, and likely cause 
for increased cases in US and Europe
• Clinical illness occurs in 40-85% of infections
• Clinical infection overlaps with Dengue and co-infection can occur
• 3-7 day incubation period, not usually a prodrome
Chikungunya Virus (CV) signs and symptoms
• Abrupt onset of high fevers (102-105°F) with shaking chills lasting 2-3 
days
• May defervesce for 4-10 days and then have a recurrence of fever for 1-2 days 
(saddle back fever)
• Pharyngitis, conjunctivitis and photophobia occur
• Severe arthralgias/myalgias and a rash are common
• Arthralgias are more common in the small joints, and often involve more than 
10 joint groups, incapacitating the patient
• Patients typically lie still in a flexed posture, avoiding movement
• Hips are usually spared, but the axial skeleton is usually involved
• Most have a complete resolution in 1-2 weeks, but some 30% develop chronic 
debilitating joint pain lasting for years
Chikungunya Virus (CV)
• Rash
• Flushed appearance of face and trunk
• Diffuse erythematous maculopapular rash involving trunk and extremities, 
sometimes including palms and soles
• Gradually fades, sometimes with petechia, xerosis, hypermelanosis or 
desquamation
• Mortality is about 10%
• More common in elderly, young and those with co-morbidities
• CV, respiratory and neurologic co-morbidities predispose to severe infection
• Not as neuroinvasive as other alpha viruses
• Neurologic disease is more common in neonates.
• Vertical transmission does occur
Chikungunya Virus (CV)
• Diagnostic Criteria
• Fever and arthralgias with history of travel to endemic area
• Dengue, Malaria, other tropical diseases excluded
• Lab
• CV specific IgM, IgG via ELISA labs take 5-7 days to become positive
• At 2-3 days viremia is high, culture may be positive if test available
• CDC offers a reverse transcriptase polymerase chain reaction (RT-PCR) test
• Treatment
• Generally supportive, NSAIDS. Caution with ASA (bleeding risk)
• Anti-virals and steroids are not effective
Dengue
• Originated in primates but moved to humans
• Most common arbovirus in humans
• Earliest outbreak was 1635 in west indies but similar illness recorded in 
China CE 265-420, associated with flying insects near water
• 1780 outbreak in North America
• Became much more common after WWII vector spread with cargo
• Vector control very effective at limiting until 1970s, resurgent since 1980s.
• 50-100 million cases/year worldwide
• 500k cases of dengue hemorrhagic fever (DHF) annually, 22k deaths
• About 250 cases/year in US; FL 2010, TX 2005
Dengue
• ssRNA virus about 11k bases, enveloped
• Enters primarily Langerhans cells and WBC via membrane fusion
• Reproduces in the cytoplasm of dendritic cells, hepatocytes, and 
endothelial cells and is shed by budding
• Four distinct serotypes
• Full immunity derived to serotype after infection, partial immunity to other
• Serotypes co-exist, infection with more than one, and infection of one after 
another is associated with more severe disease (i.e. DHF).
• Humans are the reservoir, though some primates can serve as hosts 
without developing disease.  The virus can also replicate in the vector.
• Aedes mosquitos are the vector, and are not affected by the virus.
Dengue
• Viremic host must coexist with sufficient number of vectors for 
outbreak to occur
• Follows two patterns: epidemic, and hyperendemic (ongoing)
• Patient is viremic one day before symptoms and until symptoms 
resolve (5-7 days)
• Incubation period 3-14 days, average is 4-7 days
• Initial infection is asymptomatic 50-90%, or may present as a non-
specific viral illness
• Usually self-limited
Dengue Signs and Symptoms
• May be asymptomatic, particularly if child <15 yrs old
• Recovery usually within 7-10 days
• Dengue Fever 
• Reddish mottling of skin and facial flushing
• Aching pain all over, mostly neck and back (“breakbone fever”)
• Fever begins day 3 of illness and persists 5-7 days
• Leukopenia, lymphopenia and thrombocytopenia are common
• High fever (106°F). May have “saddleback fever”: 1-2 days of fever, 
defervescence for a day, Then recurrence of fever.
• 33% of patients may have mild hemorrhagic symptoms
• Petechiae, gingival bleeding, positive tourniquet test (>20 petechiae after BP cuff)
• Rarely fatal
• Treatment is symptomatic and supportive
Dengue Signs and Symptoms
• Dengue Hemorrhagic Fever (DHF)
• Almost always occurs in those with prior exposure to Dengue
• Primarily occurs in children but can affect anyone
• Biphasic fever, when recurs will have septic shock and hemorrhagic sx
• Increasing HCT (from plasma leakage into tissues) and low albumin, atypical 
lymphocytes, transaminases elevated, thrombocytopenia
• GI bleed or other sites due to profound capillary fragility
• Ascites and/or pleural effusions due to increased capillary permeability
• DIC and severe metabolic acidosis may occur
• Mortality
• Treated 2-5%, untreated 50%.
Dengue diagnostic studies
• CBC
• LFT
• PT/INR, PTT, DIC panel if available
• UA
• Guiac
• Dengue virus IgM/IgG titer with x4 increase
• PCR for viral RNA is available at reference laboratories
• Serial US for pleural effusions shows DHF before labs are pos.
Dengue Treatment
• Usually self limited
• Supportive
• Avoid NSAIDS and ASA due to bleeding risk
• Steroids are not beneficial
• DHF should be treated in ICU
• Careful attention to fluid balance and hemorrhage
Ebola Virus
• Outbreak June 2014 – December 2015 in West Africa
• Largest Ebola outbreak in history
• 28,652 infected; 11,325 deaths
• 4 cases in US: two imported, two locally acquired
• Discovered in 1976 in Congo, near the Ebola river
• Natural reservoir is unknown, likely bats and primates
• Bats can have high viremia and not get sick, live virus present in stool
• Infected animals killed for consumption (bush meat) may contain virus
• Body fluids of infected persons are highly contagious
Ebola
• Filamentous form, enveloped, negative stranded RNA
• 5 species
• 4 cause disease in humans, 1 in animals only
• Dogs can be infected
• Relative sparing of children
• Can reproduce in all tissues
• Predilection for liver, endothelium, and mononuclear phagocytes
• Necrosis is seen in liver, spleen, lymph nodes, kidney, lung and gonads
• May inhibit adequate immune response
Ebola Clinical Course
• Primary exposure
• Travel to endemic area, incubation period 3-8 days
• Secondary exposure
• Human to human contact with infected patient, incubation period up to 21 days
• Sudden onset of
• Fever/chills, HA, myalgias/arthralgias followed quickly by GI symptoms
• Abdominal pain, N/V/D, odynophagia and dysphagia
• Half of patients will have conjunctivitis, mucus membrane/GI bleeding, and 
hemorrhage from puncture sites
• May have a maculopapular rash which desquamates in survivors
• Tachypnea is a poor prognostic indicator
Ebola Diagnostic Studies
• Virus can be detected in sweat and urine with one hour turnaround but 
is not widely available.  Most will have a 24-48 hour turnaround.
• Antigen detection test by ELISA
• IgM and IgG will be positive if patient survives long enough to mount an 
immune response.
• Thrombocytopenia and neutropenia are common.  
• Various markers of organ function will decline as organ failure occurs.
• No useful imaging tests
Ebola Treatment
• STRICT BARRIER PRECAUTIONS/ISOLATION
• All body fluids contain high numbers of infectious virions
• Supportive
• Replacement of coagulation factors
• Fluids and nutrition
• Survivors will continue to shed virions for several weeks or months 
after clinical recovery, which is slow
• Sexual transmission occurs.  Unknown how long virus remains in semen after 
clinical recovery.
• Vaccines under development
West Nile Virus (WNV)
• Arbovirus in the Flavivirus genus like Japanese encephalitis
• ssRNA with 11k bases, enveloped, enters cell by membrane fusion, 
reproduces in the cytoplasm and is shed by budding
• First discovered in 1937 in Uganda, first cases in us in 1999
• Several large outbreaks in the US. About ½ are neuroinvasive
• Since 1999 41762 cases, 18810 neuroinvasive
• 2012: 5674 cases and 256 deaths.
• 22 cases this year in CA, one death as of 8/14/16.
WNV in US and CA
WNV
• Birds are the host and reservoir
• Non-bird animals and humans are dead end hosts
• Dead birds can’t transmit the disease but are a marker of virus presence
• Not transmitted animal to person, or person to person
• Vertical transmission vector to offspring
• Culex mosquitos are the main vector
• Aedes: VHF
• Anopheles:malaria
Culex mosquito
• Worldwide distribution
• Most common mosquito in us 
cities
• Can extend to far north of 
temperate zone
• Smaller than Aedes
• No stripes
• Generally dawn/dusk or night 
feeder
WNV Signs and Symptoms
• Incubation 2-14 days but can be longer, especially if immune 
compromised
• Acute systemic febrile illness (20%)
• Headache, weakness, myalgia, or arthralgia
• Gastrointestinal symptoms 
• Maculopapular rash
• Complete recovery is the rule, sometimes with lingering fatigue
WNV Signs and Symptoms
• Neuroinvasive disease (<1%)
• Much more common in persons >50 years old and immunosupressed
• 10% mortality, mostly for encephalitis and paralysis
• Meningitis: fever, HA, nuchal rigidity
• Encephalitis: fever, altered mental status (AMS), seizures, focal neurologic 
deficits, or movement disorders
• Acute flaccid paralysis: 
• clinically identical to poliovirus-associated poliomyelitis 
• isolated limb paresis or paralysis
• can occur without fever or apparent viral prodrome
WNV Diagnostic Studies
• Serum or CSF IgM for WNV by ELISA, with PRNT to confirm
• Some cross reactivity with other Flavaviridae
• CBC
• Hyponatremia may be seen in encephalitis from SIADH
• CSF shows viral picture
• Elevated protein, lymphocytes, normal glucose
• Brain MRI usually normal but will show damage to basal ganglia, 
thalamus, and brainstem in encephalitis or damage to the anterior 
spinal cord in paralysis
WNV Treatment
• Supportive and symptomatic
• Many drugs have been tested, but none proven effective
• Monitor for development of neuroinvasive disease
• PREVENTION
• Limit outdoor activity dusk to dawn
• Use repellent, wear long sleeves
• Vector control
Meningococcus
• Neisseria meningitidis
• Encapsulated aerobic gram neg diplococci
• 13 serogroups, but 5 cause 99% of disease
• Current outbreak among MSM in southern CA.
• Natural habitat is human nasopharynx
• ~10% of population is asymptomatic carrier, up to 60% in closed populations
• Transmitted via droplet or directly via close contact
• Disease occurs when new subtype is introduced and there is a 
break in the mucosa – viral URI, smoking 
Meningococcus
• Incubation is 3-4 days (range 1-10 days)
• Most infections have mild symptoms or subclinical infection
• 10-20% of infections will become meningococcemic
• Organism reproduces rapidly and systemic symptoms occur before 
meningitis by 24-48 hours
• Endothelial necrosis, thrombosis, hemorrhage, DIC occur
• Suppurative complications occur
• Meningitis has 10% mortality even if properly treated early
• 40% mortality if meningococcal sepsis occurs with meningitis
Meningococcus workup and treatment
• Septic workup
• CBC, CMP, Lactate, blood cultures, UA, CSF studies
• CT or MRI of brain (elevated ICP common)
• LP shows elevated opening pressure, WBCs, low glucose, elevated protein
• CSF gram stain positive 70-90% 
• Rapid PCR for meningococcus is positive even if abx have been started
• Treatment
• Antibiotics (ceftriaxone very effective, higher dose), fluids, admission
• Prognosis
• 10-20% of those that recover will have some form of sequelae
Meningococcus Prevention
• Prevention
• Vaccines available for usual virulent strains
• A, B, C, W, Y
• High risk groups
• Prophylaxis for close contacts in outbreak
• ciprofloxacin for adults
• ceftriaxone for children
Meningococcal Disease in the US
Multi-Drug Resistant Organisms
• Antibiotics in use for 70 years
• Average time in use until resistance: 2-4 years
• Inappropriate or incorrect use 50% of prescriptions
• Viral, fungal organisms, partially treated.
• Pressure to satisfy/Rx
• Use in animals has greatly contributed to resistance
• CDC estimates 2.05 million illnesses and 23k deaths due to 
resistant organisms
Multi-Drug Resistant Organisms
• Urgent Category
• Clostridium difficile
• Carbapenem-Resistant 
Enterobacteriaceae (CRE)
• Includes Klebsiella and E. coli
• Some resistant to EVERYTHING
• Neisseria gonorrhoeae
• Serious Category
• Acinetobacter
• Campylobacter
• Candida
• Enterobacteriaceae (ESBL)
• Enterococcus (VRE)
• Pseudomonas
• Salmonella (typhus/non-typhus)
• Shigella
• Staphylococcus aureus (MRSA)
• Streptococcus pneumoniae
• M. tuberculosis
What can we do?
• Inpatient
• Know what types of drug-resistant 
infections are present in your 
facility and patients.
• Request immediate alerts from lab
• Alert receiving facility when you 
transfer a patient with a drug-
resistant infection.
• Follow relevant guidelines and 
precautions
• Prescribe antibiotics wisely.
• Remove temporary medical 
devices such as catheters and 
ventilators as soon as possible.
• Outpatient
• Prescribe wisely
• Narrow spectrum
• Appropriate antibiotic
• Use cultures and evidence based 
decisions to prescribe antibiotics
• Stand your ground
What is the CDC doing?
• Four core actions
1. Prevent infections
• Less illness, less antibiotic use.
2. Tracking resistance
• Identification of risk factors, control 
spread
3. Improving Antibiotic Prescribing and 
Stewardship
• Proper use in animals and humans
4. Developing New Drugs and Diagnostic Tests
• ??
Costs about $2 billion to bring new 
drug to market. Resistance in 2-4 
years. No ROI.
Vaccine Related Disease
• Many parents are reluctant to immunize because of misinformation and 
ignorance of diseases prevented by vaccination.
• Resist the urge to become frustrated
• Most research says that parents are talking to you about it because they trust 
your opinion.
• CDC website has great parent focused resources about vaccine safety.
• http://www.cdc.gov/vaccines/parents/index.html
• Finally, new law allows schools to refuse to admit unvaccinated children
• Sacramento county, 145 kids sent home 1st day of school 2016
CA Vaccine Preventable Diseases Report 2014
• H. influenzae: 40 cases, none 
type b
• Hepatitis A: 142 cases
• Hepatitis B: 108 cases
• Measles: 75 cases
• Meningococcus: 56 cases
• Mumps: 37 cases
• Pertussis: 11,213 cases
• Rubella: 2 cases 
(congenital rubella syndrome)
• Tetnus: 4 cases
• Varicella: 41 DEATHS
Most cases in SF bay area and greater LA area.
Summary
• Zika
• Chikungunya
• Dengue
• Ebola
• West Nile
• Meningitis
• Drug Resistant Organisms
• Vaccine Preventable Disease
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